Actively Recruiting
Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-12-18
30
Participants Needed
1
Research Sites
240 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC). As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.
CONDITIONS
Official Title
Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Luminal B-like breast cancer, clinical stage T1-2
- Indication for neoadjuvant chemotherapy
You will not qualify if you...
- Pregnancy
- Breast feeding
- Patient not available for follow up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
A
Alice Zamagni, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here